Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 137, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111357
Keywords
Pompe disease; Acid ?-glucosidase; Zebrafish; Neuromuscular junction (NMJ); 3; 4-Diaminopyridine phosphate (3; 4-DAPP)
Funding
- Catalyst Pharmaceuticals Inc, Coral Gables, FL, USA
Ask authors/readers for more resources
3,4-DAPP shows potential benefits in a Pompe disease model by improving NMJ structure, increasing acetylcholine receptor numbers, and enhancing zebrafish behavior.
3,4-Diaminopyridine (3,4-DAP) and its phosphate form, 3,4-DAPP have been used efficiently in the past years to treat muscular weakness in myasthenic syndromes with neuromuscular junctions (NMJs) impairment. Pompe disease (PD), an autosomal recessive metabolic disorder due to a defect of the lysosomal enzyme ?-glucosidase (GAA), presents some secondary symptoms that are related to neuromuscular transmission dysfunction, resulting in endurance and strength failure. In order to evaluate whether 3,4-DAPP could have a beneficial effect on this pathology, we took advantage of a transient zebrafish PD model that we previously generated and characterized. We investigated presynaptic and postsynaptic structures, NMJs at the electron microscopy level, and zebrafish behavior, before and after treatment with 3,4-DAPP. After drug administration, we observed an increase in the number of acetylcholine receptors an increment in the percentage of NMJs with normal structure and amelioration in embryo behavior, with recovery of typical movements that were lost in the embryo PD model. Our results revealed early NMJ impairment in Pompe zebrafish model with improvement after administration of 3,4DAPP, suggesting its potential use as symptomatic drug in patients with Pompe disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available